MHRA Safety notice on citalopram and escitalopram doses

 In Clinical Guidelines, MRHA News and Safety Alerts

A reduction in the maximum recommended doses for citalopram and escitalopram has been recommended due to the risk of QT interval prolongation.

Also, they should be used with caution with cardiac disease and ECG monitoring should be considered for patients at risk.

 

http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137769

 

Photo by Tom Varco (Own work) [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons

Recent Posts

Start typing and press Enter to search

Medicines Optimization guidancePsychosis and substance abuse